Spelling suggestions: "subject:"erostatic hyperplasia"" "subject:"erostatic hyperplasias""
81 |
Análise do perfil de expressão dos marcadores de angiogênese e das neurotrofinas na persistência da hiperatividade detrusora em pacientes submetidos à ressecção transuretal da próstata / Analysis of the expression profile of angiogenesis markers and neurotrophins in the persistence of detrusor overactive after transurethral resection of the prostate for treatment of bladder outlet obstruction due to benign prostatic hyperplasiaSilva, Marco Antonio Nunes da 14 November 2014 (has links)
Introdução: A HD está presente em aproximadamente 50% dos pacientes com OIV devido HPB e 30% dos casos não apresentarão melhora após o tratamento cirúrgico. Até o momento, nenhuma característica clínica pode predizer acuradamente quais pacientes serão beneficiados. Neste estudo nós analisamos o papel de seis marcadores moleculares na resolução da HD após a RTUP. Método: Um estudo prospectivo e controlado analisou 43 pacientes com OIV devido HPB, submetidos a RTUP de 2011 a 2012. O grupo controle foi composto por espécimes de músculo vesical de 10 pacientes com menos de 60 anos, submetidos a prostatectomia radical devido câncer de próstata, apresentando IPSS menor que 8 e volume prostático menor que 30 gramas. Todos os pacientes realizaram estudo urodinâmico no pré-operatório e com 6 meses de pós-operatório. Nós analisamos a presença, o período de início (primeira vs segunda metade do enchimento vesical) e a amplitude ( 40 cmH2O) das CVIs, assim como sua resolução após 6 meses de tratamento cirúrgico. Uma biópsia de músculo vesical foi efetuada no final da RTUP para análise do perfil de expressão gênica do NGF, NGFr, VEGF, CD-105, CHRM2 e CHRM3. Para este propósito foi utilizado a técnica de qRT-PCR. Além disso, correlacionamos variáveis clínicas pré-operatórias com a evolução da HD no pós-operatório. Resultados: A idade média dos pacientes foi 63 anos (50 a 75). A HD estava presente em 21 (48,8%) pacientes. De acordo com aferições pré-operatórias, a média de expressão gênica do NGF foi 3,3 vezes maior nos pacientes que iniciaram CVI precocemente quando comparados àqueles que iniciaram as contrações na fase final de enchimento vesical (p=0,047). A presença e a amplitude das CVIs não apresentaram correlações estatísticas com os genes estudados. Em relação a resolução da HD, a média de expressão de CHRM2 foi 2 vezes maior entre os pacientes que evoluíram com melhora da HD (p=0,072). Após 6 meses da RTUP, 77,8% dos pacientes que possuíam expressão aumentada (maior que a mediana) de CHRM2 CHRM3 evoluíram com resolução da HD (p=0,030). Além disso, pacientes com menos de 60 anos obtiveram uma probabilidade 5 vezes maior de evoluírem com melhora da HD (p=0,056) após 6 meses do tratamento cirúrgico. Conclusão: Vias neuronais parecem estar relacionadas com o período de início das CVIs durante a fase de enchimento vesical. A idade dos pacientes e a expressão de receptores muscarínicos pode ter um papel prognóstico na resolução da hiperatividade após o tratamento cirúrgico. A análise de um número maior de pacientes é necessário para confirmar estes resultados / Objective: Non-inhibited contractions (NIC) are present in about 50% of patients with bladder outlet obstruction (BOO) due to benign prostatic hyperplasia (BPH) and 30% of cases persist after surgery. To date, no clinical characteristic can predict accurately which patients are going to improve. We analyzed the role of six detrusor molecular markers in the resolution of NIC after transurethral resection of the prostate (TURP). Methods: We performed a prospective and controlled analysis of 43 patients with BOO due to BPH who underwent TURP from 2011 to 2012. The control group comprised 10 bladder specimens from patients younger than 60 years who underwent radical prostatectomy with an IPSS < 8 and prostate volume < 30 grams. All patients underwent urodynamic analysis pre and post operatively after 6 months. We analyzed the presence, time to occurrence (first vs second half of the filling phase) and grade (40 cmH2O) of NIC as well as its resolution after 6 months of surgery. A biopsy of the bladder muscle was performed at the end of TURP for analysis of nerve growth factor receptor (NGFr), nerve growth factor (NGF), vascular endothelial growth factor (VEGF), endoglin (CD105), muscarinic cholinergic receptor 2 (CHRM2) and muscarinic cholinergic receptor 3 (CHRM3) genes expression. For this purpose, we used the quantitative real time polymerase chain reaction method (qRT-PCR). Results: Mean patient age was 63 years (50 to 75). NIC were present in 21 (48.8%) patients. According to pre-operative measures, NGF gene expression was 3.3 times greater in patients who presented early NIC as compared to those who presented late contractions (p=0.047). The presence or grade of NIC failed to present statistical correlations with the genes. With regard to the outcome, CHRM2 expression was 2.0 times greater among patients who presented resolution of NIC (p=0.072). After 6 months of TURP, 77,8% of patients with DO resolution had increased expression of CHRM2 and CHRM3 genes compared with others cases (p=0,030). Additionally, patients younger than 60 years obtained a 5.0 times more likely to evolve with improved NIC (p=0,056). Conclusion: Neural pathways seem to be more important in the time to NIC occurrence during the filling phase. Muscarinic cholinergic receptors seem to have a prognostic value in the resolution of NIC after surgery. Analysis of greater number of patients is necessary to confirm these results
|
82 |
Avaliação dos biomarcadores urinários de inflamação e de remodelação tecidual na disfunção vesical em pacientes com hiperplasia prostática benigna / Evaluation of urinary biomarkers of inflammation and tissue remodeling in bladder dysfunction in patients with benign prostatic hyperplasiaConti, Paulo Sajovic de 08 February 2019 (has links)
INTRODUÇÃO: A HD está presente em aproximadamente 50% dos pacientes com OIV devido HPB e 30% dos casos não apresentarão melhora após o tratamento cirúrgico. Até o momento, nenhuma característica clínica pode predizer acuradamente quais pacientes serão beneficiados. Há espaço para o aprimoramento de novos métodos diagnósticos não invasivos capazes de discriminar quais os melhores candidatos à cirurgia. Neste estudo nós analisamos o papel de cinco biomarcadores urinários moleculares associados à HD e à OIV em pacientes com HPB que serão submetidos à RTUP. MÉTODOS: Um estudo prospectivo e controlado analisou 71 pacientes candidatos à RTUP devido HPB, submetidos ao procedimento cirúrgico entre 2011 a 2016. O grupo controle foi composto por pacientes assintomáticos apresentando IPSS menor que 6, volume prostático menor que 30 gramas, ausência de resíduo pósmiccional e fluxometria máxima >= 15ml/s. Todos os pacientes do grupo de estudo realizaram estudo urodinâmico no pré-operatório e 63 pacientes no período pósoperatório. Nós analisamos a presença, o período de início (primeira vs segunda metade do enchimento vesical) e a amplitude ( 40 cmH2O) das CVIs, assim como o grau de obstrução infravesical. A coleta da urina foi realizada no pré-operatório para os pacientes do grupo de estudo. A urina foi analisada para 5 quimiocinas, citocinas e fatores de crescimento usando teste de ELISA. Os valores de concentração das proteínas foram analisados de forma absoluta e normalizados para os níveis de creatinina (/Cr). RESULTADOS: A idade média dos pacientes foi 67 anos (50 a 88). A HD estava presente em 39 (54,9%) pacientes. De acordo com aferições pré-operatórias, a média da concentração urinária de IL-6/Cr (p=0,007), MCP-1(p=0,000), MCP-1/Cr (p=0,000), EFG/Cr (p=0,044) e MMP-1/Cr (p=0,043) estavam respectivamente cerca de 4,5x, 7,1x, 23x, 1,7x e 2,2x vezes significativamente aumentadas em relação aos controles assintomáticos. O nível de EGF foi 1,3 vezes maior nos pacientes que iniciaram CVI tardiamente quando comparados àqueles que iniciaram as contrações na fase inicial de enchimento vesical (p=0,044). A amplitude das CVIs, o fluxo urinário, a complacência, o índice de contratilidade, e o schafer não apresentaram correlações estatísticas com as proteínas estudadas. Em relação a presença de HD, os níveis urinários de IL-6 (p=0,003), MCP-1(p=0,002), e MCP-1/Cr (p=0,002) foram respectivamente 1,8x, 2x, e 2,7 vezes aumentados em relação aos pacientes submetidos à cirurgia sem HD ao estudo urodinâmico. O MCP-1/Cr foi o marcador com melhores propriedades diagnósticas para HD, apresentando área sob a curva (AUC) de 0,71 (95% CI 0,59 a 0,84). A dosagem do MCP-1 não ajustada pela creatinina apresentou uma AUC de 0,71 (95% CI 0,59 a 0,83). A IL-6, por sua vez, teve uma AUC de 0,70 (95% CI 0,58 a 0,82). Todos os outros biomarcadores apresentaram propriedades inadequadas neste cenário para avaliação da HD e OIV. Em relação à resolução ou persistência da HD após 12 meses de tratamento cirúrgico, os níveis dos biomarcadores NGF/Cr (p=0.005) e MMP-1/Cr (p=0.021) foram superiores entre os pacientes que não obtiveram interrupção das CVIs no pós-operatório. Demonstraram serem úteis para predizer a persistência da HD no pós-operatório, o NGF/Cr com AUC de 0,77 (95% CI 0,62 à 0,92) (p=0,006) e o MMP-1/Cr com AUC de 0,72 (95% CI 0,56 à 0,88) (p=0,022). CONCLUSÕES: Vias neuronais parecem estar relacionadas com o período de início das CVIs durante a fase de enchimento vesical. A presença de níveis elevados na urina de biomarcadores inflamatórios e de reparo tecidual sugere um papel da inflamação na gênese da HD, e pode ajudar no diagnóstico não invasivo deste achado no pré-operatório. MCP-1, MCP-1 /Cr e IL-6 foram associados a presença de de HD ao estudo urodinâmico em pacientes com HPB candidatos a RTUP. O nível de EGF/Cr foi associado a contrações vesicais tardias. O MMP-1/Cr foi relacionado a maior pressão detrusora. O biomarcador MCP-1/Cr demonstrou-se ser útil no diagnóstico de HD nos pacientes com HPB. NGF/Cr e MMP-1/Cr demonstraram-se ser úteis para predizer a persistência da HD no pós-operátorio / INTRODUCTION: Detrusor hyperactivity (DH) is present in approximately 50% of patients with bladder outlet obstruction (BOO) due to benign prostatic hyperplasia (BPH), and 30% of the cases will not show improvement after surgical treatment. To date, no clinical feature can accurately predict which patients will benefit from surgical treatment. This rate can be improved because new noninvasive diagnostic methods are capable of determining the best candidates for surgery. In this study, we analyzed the role of five molecular biomarkers in urine associated with DH and BOO in patients with BPH undergoing transurethral resection of the prostate (TURP). METHODS: This prospective and controlled study analyzed 71 patients who were candidates for TURP due to BPH and underwent surgery between 2011 and 2016. The control group consisted of asymptomatic patients with International Prostate Symptom Scores (IPSSs) less than 6, prostate volume less than 30 grams, absence of estimated postvoid residual volume and a maximum flow rate >= 15 ml/s. All patients in the study group underwent a preoperative urodynamic study, with 63 patients undergoing a repeat urodynamic study during the postoperative period. We analyzed the presence, onset period (first vs second half of bladder filling) and amplitude ( 40 cmH2O) of the involuntary detrusor contractions (IDCs), as well as the degree of BOO. Urine was collected preoperatively from patients in the study group. The urine was analyzed for five chemokines, cytokines and growth factors using ELISAs. The protein concentrations were analyzed as absolute and creatinine (/Cr)-adjusted values. RESULTS: The mean age of the patients was 67 years (50 to 88). DH was present in 39 (54.9%) patients. According to preoperative measurements, the mean urine concentrations of IL-6/Cr (p = 0.007), MCP-1 (p = 0.000), MCP-1/Cr (p = 0.000), EGF/Cr (p = 0.044) and MMP-1/Cr (p = 0.043) were approximately 4.5, 7.1, 23, 1.7 and 2.2 times, respectively, those of asymptomatic controls (all significantly increased). The EGF level was 1.3 times higher in patients with late IDCs than in those whose contractions started in the early stage of bladder filling (p = 0.044). The IDC amplitude, urinary flow, compliance, bladder contractility index, and Schafer\'s grade were not significantly correlated with the proteins studied. In patients with DH, urinary levels of IL-6 (p = 0.003), MCP-1 (p = 0.002), and MCP- 1/Cr (p = 0.002) were 1.8, 2, and 2.7 times higher, respectively, than in patients without DH who underwent surgery, according to the urodynamic study. MCP- 1/Cr had the best diagnostic properties for DH, with an area under the curve (AUC) of 0.71 (95% CI: 0.59 to 0.84). The non-Cr adjusted MCP-1 concentration had an AUC of 0.71 (95% CI: 0.59 to 0.83). Additionally, IL-6 had an AUC of 0.70 (95% CI: 0.58 to 0.82). All other biomarkers were inadequate for DH and BOO evaluation. Regarding the resolution or persistence of DH 12 months after surgery, the NGF/Cr (0.13 vs 0.08, p = 0.005) and MMP-1/Cr (0.11 vs 0.04, p = 0.021) levels were higher in patients for whom the IDCs continued during the postoperative period. The following factors were shown to be useful for predicting the persistence of DH during the postoperative period: NGF/Cr, with an AUC of 0.77 (95% CI: 0.62 to 0.92) (p = 0.006), and MMP-1/Cr, with an AUC of 0.72 (95% CI: 0.56 to 0.88) (p = 0.022). CONCLUSIONS: Neural pathways appear to be related to the onset period of IDCs during bladder filling. The presence of high urinary levels of inflammatory and tissue repair biomarkers suggests a role of inflammation in the genesis of DH and may aid in the noninvasive diagnosis of this condition during the preoperative period. MCP-1, MCP-1/Cr and IL-6 were associated with the presence of DH in the urodynamic studies of patients with BPH who were candidates for TURP. The EGF/Cr level was associated with late detrusor contractions. MMP-1/Cr was associated with increased detrusor pressure. The MCP-1/Cr biomarker was shown to be useful for the diagnosis of DH in patients with BPH. NGF/Cr and MMP-1/Cr were shown to be useful in predicting the persistence of DH during the postoperative period
|
83 |
Sexual and reproductive health problems among Aboriginal and Torres Strait Islander malesAdams, Michael John January 2007 (has links)
Compared to males in almost any social group in all affluent nations, Australia's Aboriginal and Torres Strait Islander men suffer from substantially more serious illnesses and early death. To date, research done by or in collaboration with Indigenous communities has revealed the extent of the problems that arise from diabetes, heart disease, hypertension, cancers, respiratory diseases, psychological disorders, accidental injuries, violence and other causes. Reproductive health, however, rarely has been studied among Indigenous men. To date, research in this field has been limited mainly to studies of sexually transmitted infections. No data has been published on Aboriginal men's symptoms of prostate disease or erectile dysfunction, nor has the clinical screening and treatment of these disorders among these men been assessed. In-depth search of the worldwide web demonstrated that little information on these issues was available from other Indigenous populations. It does appear that Indigenous men in Australia, New Zealand and North America are less likely than European-ancestry men to die from prostate cancer, or for living cases to be recorded on cancer registries. This may arise because Indigenous men genuinely have a lower risk, or because they are not captured by official statistics, or because they do not live long enough to develop severe prostate disease. We also know very little about other reproductive health problems such as sexual dysfunction and specifically erectile difficulties. One reason for our scant knowledge is that research mainly relies on self-report of sensitive information. The aim of the research study was to improve the understanding of sexual and reproductive health problems experienced by Indigenous men. This is best gathered by Aboriginal males who are inside the culture of middleaged and older Indigenous men, but until now this has not been attempted. In this study we adopted the World Health Organization (WHO) definitions for Reproductive and Sexual Health (WHO, 2001). Thus, we consider reproductive system disorders (prostate disease, erectile dysfunction) and related health care-seeking, and also men's perceptions about a "satisfying and safe sexual life". The methodology was framed within an Aboriginal and Torres Strait Islander research protocol that advocates respect for cultural, social and community customs. A mixed method design combined qualitative inquiry (4 focus groups and 18 in-depth interviews) and quantitative survey (n=301) involving men living in remote, rural and urban communities (Tiwi Islands, Darwin and north and south-east Queensland). Survey data were compared to recently published self-reports from 5990 randomly selected men aged over 40 years in Australia (Holden et al., 2005, The Lancet, 366, 218-224. The qualitative interviews revealed that most men were silent about reproductive health. They were unwilling to reveal their inner feelings to wives or partners, and they were unwilling to discuss such issues with doctors and other health care workers. Men's reaction to sexual difficulties included shame, denial, substance abuse and occasionally violence. On a positive note many men said they want to learn about it, so they understand how to cope with such problems. The Indigenous men reported symptoms of erectile dysfunction at least as much as non-Indigenous men in other Australian studies. Bivariate analysis showed that erectile dysfunction was correlated with many health and lifestyle variable. However multivariate analysis revealed that only three factors significantly predicted ED: presence of chronic disease, presence of pain when working, and living in a remote geographic location The quantitative survey data indicate that Indigenous men have more symptoms of prostate disease than non-Indigenous men. The syndrome appears to be poorly managed in clinical practice (e.g. rates of PSA testing and digital-rectal examination are only one-third the rate reported by non-Aboriginal men, despite equivalent likelihood of GP visits). The research study adds to the literature by providing better insight and depth into the issues impacting on Aboriginal and Torres Strait Islander males experiencing reproductive and sexual health difficulties. It also provides a platform to undertake comprehensive research with Aboriginal and Torres Strait Islander men to explore a wider spectrum of questions in this important but neglected area. Implications for education of primary healthcare workers and community-based awareness campaigns for Indigenous males are discussed. Most of all, this study revealed "layers" of silence around sexual and reproductive health of Indigenous men. This includes silence in the scientific establishments in health services, and in the community. It is hoped that this study puts the voices of the men forward to help to break down this silence.
|
84 |
Variações transcricionais dos genes AR, SRD5A2, KLK2, PCA3, KLK3 e PSMA e implicações no diagnóstico molecular do câncer de próstataNeves, Adriana Freitas 26 February 2007 (has links)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / CHAPTER I -
Prostate cancer is a common disease in the world and in some countries it is one of the
main causes of male population mortality. Some molecular markers have been associated
with prostate carcinogenesis. To observe changes in transcript levels of the AR, SRD5A2,
KLK2, PSMA and PCA3 genes, the mRNA was analyzed in tissues with prostatic
adenocarcinoma (PCa, N= 48) and benign prostatic hyperplasia (BPH, N= 25), performed
through a differential multiplex RT-PCR assay. Significant differences were observed in
the relative expression of these genes between cancerous and non-cancerous tissues.
The optical density ratio of the cDNA amplicons between PCa and BPH for the AR gene
was 1.6-fold higher for the prostatic adenocarcinoma. On the other hand, the SRD5A2
mRNA levels were associated with BPH and were 1.4-fold higher than that of PCa. For
KLK2, PSMA and PCA3, the transcriptional levels were respectively, 1.9-, 1.9- and 5-fold
higher in PCa than those in BPH tissues. Of the diagnostics tests carried through
individually, the PCA3 gene was that presented higher sensitivity and accuracy, and the
inclusion of the serum PSA improved the sensitivity (of 76 to 92%), positive preditive value
(of 85 to 94%), negative preditive value (of 60 to 62%) and accuracy (of 74 to 78%). The
results suggest that the higher AR, KLK2, PSMA, and PCA3 and/or reduced SRD5A2
genes expression in prostatic tissues may indicate the occurrence of prostate
adenocarcinoma; however the PCA3 and serum PSA analysis together are highly
promising as auxiliary method in the diagnosis of this cancer.
CHAPTER II -
Purpose: Prostate cancer (PCa) is the most commonly diagnosed malignancy in men, and
it consists of multifactorial and multifocal events. Due to the complexity of the disease
process, which includes genome alterations, local invasion, micrometastatic cell
extravasations to circulation, invasion of secondary organ tissues, and resistance to
hormonal blockage, many markers must be used to represent the multiple and variable
events that lead to cancer development. The low specificity of the unique serum marker
for prostate cancer diagnostics, PSA, has leaded us to investigate four potential markers
in the peripheral blood of patients by detecting their mRNA levels and associating them to
clinical parameters. Methods: The expression levels of the KLK2, KLK3, PCA3 and PSMA
transcripts were determined by Nested RT-PCR. Patients with PCa (99) and with benign
prostatic hyperplasia (BPH, 36), and healthy volunteers (104) were investigated. Results:
Significant differences for the RNA relative levels have been found for the KLK2, PCA3
and PSMA transcripts between PCa and BPH patients or healthy volunteers. The KLK2
and PSMA levels also presented a positive association (P<0.05) with extra-prostatic
disease (pT3). The combined positive RT-PCR Nested for the KLK2, PCA3, PSMA genes
with serum PSA higher than 4ng/mL presented a 10-fold higher chance of cancer
occurrence than healthy controls, with sensitivity, specificity and positive predictive value
of 57%, 89% and 93%, respectively. Conclusions: The combined analysis of KLK2, PCA3
and PSMA transcripts may become a useful tool for the discrimination of PCa patients
from those with benign disease or healthy individuals. Additionally, the KLK2 and PSMA
transcripts may also be used as prognostic markers for the presence of extra-capsular
disease and assisting in the prediction of the post-operative outcome.
CHAPTER III -
Purpose: Transcripts of PCA3/DD3 gene are at the moment the most specific molecule
found in prostate cancer specimens. This mRNA can be detected in important sample
targets for clinical analyses, such as prostatic tissues, urine after prostatic massage, and
the peripheral blood. Methods: The present study evaluated the PCA3 gene expression in
prostatic tissues and in peripheral blood of BPH and PCa patients, by RT-PCR assays,
and based on its detection together with other clinical parameters, we proposed a model
for molecular monitoring in order to improve diagnosis as an auxiliary technology. Results:
The concomitant use of PCA3 transcript detection in the peripheral blood and in prostate
tissues has improved diagnosis, with sensitivity and an accuracy of 77%. For the
molecular staging, patients have been classified as: localized disease (PBL-; negative
PCA3) and circulating tumors cells disease (PBL+; positive PCA3). The higher
frequencies of PBL- had been observed in T1-T2 stages (75%); on the other hand, the
higher PCA3 positivity was observed for the T3-T4 staging (43%), while the T1-T2 stages
presented 25% positivity. A correlation was found between the molecular staging and
serum PSA < 10ng/mL before surgery, and approximately 60% of patients with T3-T4
stages that presented biochemical failure after radical prostatectomy presented a positive
PCA3 result (P= 0.05), with an odds ratio of 16-fold higher for the possibility of disease
recurrence in relation to the T1-T2 patients, and an accuracy of 82%. Conclusion: These
data demonstrated the importance of the PCA3 gene as an auxiliary method in prostate
cancer diagnosis, by distinguishing PCa from BPH patients, and also demonstrated its
prognostic value in recurrent disease for post-operative patients.
CHAPTER IV -
Approximately 98% of all the products transcribed in the human genome correspond to
non coding RNAs (ncRNA). Many ncRNA functions are attributed to this structural
particularity given mainly for the secondary structures formed from its linear sequence of
bases. Among the ncRNA types are tRNA, rRNA, small nuclear RNA, small nucleolar
RNA, small interference RNA (siRNA), microRNA (miRNA) and catalytic RNAs
(ribozymes). The bioinformatics has supplied useful tools in the prediction of optimal or
suboptimal secondary structures allowing the design of interference RNA as miRNAs or
siRNAs. In human, miRNAs have been associated with the development of diverse
complex diseases as cancer. The PCA3 (DD3) gene was molecularly characterized as
cancer and prostate specific, and its transcripts are non-coding, once no peptide products
have been found. Due to its structural characteristics, the PCA3 gene belongs thus to the
increasing family of ncRNA. In the present work, four new variant molecules of the PCA3
gene have been sequence characterized and their frequencies demonstrated in prostate
cancer and in benign prostatic hyperplasia patients, as well as in healthy individuals. We
have also investigated and predicted the putative secondary structures formed in order to
elucidate its role in prostate cancer biology. No association has been found between the
frequency of these molecules and prostate pathologies (PCa or BPH). On the other hand,
PCA3 variants were found in 10% (12/115) of cases in the general population. Similar
analyses of the possible polypeptides of these molecules demonstrated that it remains as
a non-coding RNA, and introns presents in the first, second and fourth variants suggesting
a possible role as a miRNA with intracellular activity to these molecules to the PCA3 gene.
In prostatic tissues, 100% of the prostate cancer cases presented the RNA molecule with
an exon 2 splicing. However, further investigation must be carried out to demonstrate the
true role of these splicing variants in prostate tumors and in other pathologies, once these
molecules have been preferentially found in the peripheral blood. / CAPÍTULO I -
O câncer de próstata é uma doença comum no mundo e já assumiu em alguns
países uma das principais causas de mortalidade da população masculina. Vários
marcadores moleculares têm sido associados à gênese do câncer de próstata. A fim de
demonstrar a expressão diferencial dos níveis transcricionais dos genes AR, SRD5A2,
KLK2, PSMA e PCA3 em doenças prostáticas, o RNAm foi analisado em tecidos com
adenocarcinoma prostático (CaP, N= 48) e hiperplasia prostática benigna (HPB, N= 25)
por meio da técnica RT-PCR multiplex semi-quantitativa. Foram observadas diferenças
significativas na expressão relativa desses genes entre os tecidos cancerosos e nãocancerosos.
A taxa de densidade ótica entre os amplicons para cDNA provenientes do
gene AR foi 1.6 vezes maior no adenocarcinoma prostático. Por outro lado, os níveis de
RNAm do gene SRD5A2 foi associado com a HPB e foi 1.4 vezes maior do que no CaP.
Para os genes KLK2, PSMA e PCA3, os níveis transcricionais foram respectivamente,
1.9, 1.9 e 5 vezes maior no câncer comparado a tecidos benignos. Dos testes
diagnósticos realizados, o gene PCA3 individualmente foi o que apresentou as melhores
sensibilidade e acurácia, sendo que a inclusão das medidas de PSA sérico melhorou a
sensibilidade (de 76 para 92%), o valor preditivo positivo (de 85 para 94%), o valor
preditivo negativo (de 60 para 62%) e a acurácia (de 74 para 78%). Os dados sugerem
que a maior expressão dos genes AR, KLK2, PSMA e PCA3 ou expressão reduzida do
gene SRD5A2 em tecidos prostáticos podem indicar a ocorrência do adenocarcinoma da
próstata, sendo que as análises do gene PCA3 juntamente aos do PSA sérico são
altamente promissores como método auxiliar no diagnóstico desse tipo de câncer.
CAPÍTULO II -
O câncer de próstata (CaP) e o mais comumente diagnosticado na população masculina
e consiste de eventos multifatoriais e multifocais. Devido a complexidade da doença, a
qual inclui alterações genômicas, invasão local, liberação de células micrometastáticas
para a circulação, invasão secundaria de tecidos de outros órgãos, e resistência ao
bloqueio hormonal, muitos marcadores podem ser usados para representar os eventos
múltiplos e variáveis que levam ao desenvolvimento do câncer. A baixa especificidade do
único marcador para diagnostico do câncer de próstata, PSA, tem nos levado a investigar
quatro potenciais marcadores no sangue periférico de pacientes pela detecção de seus
níveis de RNAm e associá-los a parâmetros clínicos. Os níveis de expressão dos
transcritos do KLK2, KLK3, PCA3 e PSMA foram avaliados pela RT-PCR Nested, em
pacientes com CaP (99), com hiperplasia prostática benigna (HPB, 36) e voluntários
saudáveis (104). Diferenças significativas foram encontradas para a expressão dos genes
KLK2, PSMA e PCA3 entre os pacientes com CaP e os pacientes com HPB ou
voluntários saudáveis. Os níveis do KLK2 e PSMA também apresentaram associação
positiva (P<0.05) com doença extra-prostática (pT3). A RT-PCR Nested positiva
combinada para os genes KLK2, PCA3 e PSMA com PSA sérico maior que 4ng/mL
apresentou uma chance 10 vezes maior de ocorrência do câncer comparado aos
controles saudáveis, com sensibilidade, especificidade e acurácia de 57%, 89% e 93%,
respectivamente. A análise combinada dos genes KLK2, PCA3 e PSMA pode ser uma
ferramenta útil na distinção de pacientes com CaP daqueles com doença benigna ou de
indivíduos saudáveis. Ainda, a analise dos transcritos KLK2 e PSMA podem ser usados
como marcadores prognósticos para a presença de doença extra-capsular e auxiliando
na predição de recidiva da doença no pós-operatório.
CAPÍTULO III -
Os transcritos do gene PCA3/DD3 são até o momento as moléculas mais específicas
encontradas em espécimes de câncer de próstata. Esses RNAm podem ser detectados
em importantes alvos para a análise clínica como tecidos prostáticos, na urina após
massagem prostática e em sangue periférico. O presente estudo avaliou a expressão do
gene PCA3 em tecidos prostáticos e em sangue periférico de pacientes com HPB e CaP,
por técnicas de RT-PCR, e baseado na sua detecção juntamente com os parâmetros
clínicos, foi proposto um modelo de estadiamento molecular como técnica assessória
para melhor o diagnóstico da doença. O uso concomitante da detecção dos transcritos do
gene PCA3 no sangue periférico e no tecido prostático melhorou o diagnóstico, com
sensibilidade e acurácia de 77%. Para o estadiamento molecular, os pacientes foram
classificados como contendo a doença localizada (PBL-) e em doença com células
tumorais circulantes (PBL +). Maiores freqüências de tumor localizado pelo estadiamento
molecular foram observadas nos estadios T1-T2 (75%), enquanto que 25 e 43% dos
cânceres T1-T2 e T3-T4, respectivamente, apresentaram PCA3 positivo (células
circulantes). Uma correlação foi encontrada para o estadiamento molecular para doença
localizada e PSA sérico pré-cirúrgico < 10ng/mL, e aproximadamente 60% dos pacientes
TNM T3-T4 que apresentaram falha bioquímica após a cirurgia radical apresentaram RTPCR
positiva do PCA3 (P= 0.05), com um Odds Ratio 16 vezes maior para a
possibilidade de recorrência da doença em relação aos pacientes T1-T2 e uma acurácia
de 82%. Esses dados demonstram a importância da detecção do gene PCA3 como
método no diagnóstico do câncer de próstata, por distinguir pacientes com CaP daqueles
com HPB, e também demonstrando seu valor prognóstico na doença recorrente no pósoperatório
dos pacientes.
CAPÍTULO IV -
Aproximadamente 98% de todos os produtos transcritos do genoma humano
correspondem a RNAs não codificantes (RNAnc). Muitas funções dos RNAnc são
atribuídas a suas particularidades estruturais dadas principalmente pelas estruturas
secundárias formadas a partir da sua sequência linear de bases. Dentre os tipos de
RNAnc estão os RNAt, RNAr, small nuclear RNA, small nucleolar RNA, small interference
RNA (siRNA), microRNA (miRNA) e RNAs catalíticos (ribozimas). A bioinformática tem
fornecido ferramentas úteis na predição de estruturas secundárias ótimas ou subótimas
permitindo o design de RNAs de interferência como os miRNAs ou siRNAs. Em humanos,
os miRNAs tem sido associados ao desenvolvimento de diversas doenças complexas
como o câncer. O gene PCA3 (DD3) foi molecularmente caracterizado como câncer- e
próstata- específico e os seus RNAs são os responsáveis por essa característica, isso
porque nenhum produto protéico tem sido encontrado para esse gene. Devido às suas
características estruturais, o gene PCA3, pertence assim à crescente família de RNAnc.
No presente trabalho foi analisado as freqüências de quatro moléculas variantes do gene
PCA3, além das anteriormente reportadas, como também foram preditas as suas
estruturas secundárias na tentativa de elucidar o seu papel na biologia do câncer de
próstata. Nenhuma associação foi encontrada entre a freqüência dessas moléculas e as
patologias da próstata como hiperplasia benigna ou câncer, sendo que na população
geral analisada essas variantes foram encontradas em apenas 10% (12/115) dos casos.
As análises de homologia de possíveis polipeptídeos para essas moléculas demonstram
que permanece o papel de RNA não-codificante para o gene PCA3. Ainda, a presença de
introns nas variantes 1, 2 e 4 podem sugerir um papel intracelular de miRNA para essas
moléculas do gene PCA3. Nos tecidos prostáticos, 100% dos casos de câncer foi
representando pela molécula com splicing do exon 2. Contudo, para as variantes de
splicing, novas pesquisas deverão ser realizadas incluindo outras patologias além das
doenças prostáticas e outros tipos tumorais para verificar o real impacto dessas
moléculas, uma vez que foram encontradas preferencialmente no sangue periférico. / Doutor em Genética e Bioquímica
|
85 |
Análise do perfil de expressão dos marcadores de angiogênese e das neurotrofinas na persistência da hiperatividade detrusora em pacientes submetidos à ressecção transuretal da próstata / Analysis of the expression profile of angiogenesis markers and neurotrophins in the persistence of detrusor overactive after transurethral resection of the prostate for treatment of bladder outlet obstruction due to benign prostatic hyperplasiaMarco Antonio Nunes da Silva 14 November 2014 (has links)
Introdução: A HD está presente em aproximadamente 50% dos pacientes com OIV devido HPB e 30% dos casos não apresentarão melhora após o tratamento cirúrgico. Até o momento, nenhuma característica clínica pode predizer acuradamente quais pacientes serão beneficiados. Neste estudo nós analisamos o papel de seis marcadores moleculares na resolução da HD após a RTUP. Método: Um estudo prospectivo e controlado analisou 43 pacientes com OIV devido HPB, submetidos a RTUP de 2011 a 2012. O grupo controle foi composto por espécimes de músculo vesical de 10 pacientes com menos de 60 anos, submetidos a prostatectomia radical devido câncer de próstata, apresentando IPSS menor que 8 e volume prostático menor que 30 gramas. Todos os pacientes realizaram estudo urodinâmico no pré-operatório e com 6 meses de pós-operatório. Nós analisamos a presença, o período de início (primeira vs segunda metade do enchimento vesical) e a amplitude ( 40 cmH2O) das CVIs, assim como sua resolução após 6 meses de tratamento cirúrgico. Uma biópsia de músculo vesical foi efetuada no final da RTUP para análise do perfil de expressão gênica do NGF, NGFr, VEGF, CD-105, CHRM2 e CHRM3. Para este propósito foi utilizado a técnica de qRT-PCR. Além disso, correlacionamos variáveis clínicas pré-operatórias com a evolução da HD no pós-operatório. Resultados: A idade média dos pacientes foi 63 anos (50 a 75). A HD estava presente em 21 (48,8%) pacientes. De acordo com aferições pré-operatórias, a média de expressão gênica do NGF foi 3,3 vezes maior nos pacientes que iniciaram CVI precocemente quando comparados àqueles que iniciaram as contrações na fase final de enchimento vesical (p=0,047). A presença e a amplitude das CVIs não apresentaram correlações estatísticas com os genes estudados. Em relação a resolução da HD, a média de expressão de CHRM2 foi 2 vezes maior entre os pacientes que evoluíram com melhora da HD (p=0,072). Após 6 meses da RTUP, 77,8% dos pacientes que possuíam expressão aumentada (maior que a mediana) de CHRM2 CHRM3 evoluíram com resolução da HD (p=0,030). Além disso, pacientes com menos de 60 anos obtiveram uma probabilidade 5 vezes maior de evoluírem com melhora da HD (p=0,056) após 6 meses do tratamento cirúrgico. Conclusão: Vias neuronais parecem estar relacionadas com o período de início das CVIs durante a fase de enchimento vesical. A idade dos pacientes e a expressão de receptores muscarínicos pode ter um papel prognóstico na resolução da hiperatividade após o tratamento cirúrgico. A análise de um número maior de pacientes é necessário para confirmar estes resultados / Objective: Non-inhibited contractions (NIC) are present in about 50% of patients with bladder outlet obstruction (BOO) due to benign prostatic hyperplasia (BPH) and 30% of cases persist after surgery. To date, no clinical characteristic can predict accurately which patients are going to improve. We analyzed the role of six detrusor molecular markers in the resolution of NIC after transurethral resection of the prostate (TURP). Methods: We performed a prospective and controlled analysis of 43 patients with BOO due to BPH who underwent TURP from 2011 to 2012. The control group comprised 10 bladder specimens from patients younger than 60 years who underwent radical prostatectomy with an IPSS < 8 and prostate volume < 30 grams. All patients underwent urodynamic analysis pre and post operatively after 6 months. We analyzed the presence, time to occurrence (first vs second half of the filling phase) and grade (40 cmH2O) of NIC as well as its resolution after 6 months of surgery. A biopsy of the bladder muscle was performed at the end of TURP for analysis of nerve growth factor receptor (NGFr), nerve growth factor (NGF), vascular endothelial growth factor (VEGF), endoglin (CD105), muscarinic cholinergic receptor 2 (CHRM2) and muscarinic cholinergic receptor 3 (CHRM3) genes expression. For this purpose, we used the quantitative real time polymerase chain reaction method (qRT-PCR). Results: Mean patient age was 63 years (50 to 75). NIC were present in 21 (48.8%) patients. According to pre-operative measures, NGF gene expression was 3.3 times greater in patients who presented early NIC as compared to those who presented late contractions (p=0.047). The presence or grade of NIC failed to present statistical correlations with the genes. With regard to the outcome, CHRM2 expression was 2.0 times greater among patients who presented resolution of NIC (p=0.072). After 6 months of TURP, 77,8% of patients with DO resolution had increased expression of CHRM2 and CHRM3 genes compared with others cases (p=0,030). Additionally, patients younger than 60 years obtained a 5.0 times more likely to evolve with improved NIC (p=0,056). Conclusion: Neural pathways seem to be more important in the time to NIC occurrence during the filling phase. Muscarinic cholinergic receptors seem to have a prognostic value in the resolution of NIC after surgery. Analysis of greater number of patients is necessary to confirm these results
|
86 |
Análise da expressão das metaloproteinases e seus inibidores teciduais no músculo detrusor de pacientes com obstrução infravesical por hiperplasia prostática benigna / Expression of metalloproteinases and their tissue inhibitors in the detrusor muscle of patients with bladder outlet obstruction due to benign prostatic hyperplasiaFerreira, Yuri Afonso 03 October 2014 (has links)
Introdução: A obstrução infravesical (OIV) de longo prazo secundária a hiperplasia prostática benigna (HPB) pode causar alterações funcionais e morfológicas na bexiga. Um dos principais eventos consiste no aumento da deposição de colágeno e perda de complacência vesical, levando a alteração de armazenamento e esvaziamento urinário. O aumento da deposição de colágeno na matriz extracelular (MEC) da musculatura detrusora é a principal razão para a diminuição da complacência vesical. Na bexiga, assim como em outros órgãos, este fenômeno depende da atividade equilibrada de enzimas proteolíticas, incluindo as metaloproteinases (MMP) e os seus inibidores endógenos (inibidores teciduais de metaloproteinases-TIMPs). Como estes fenômenos são desconhecidos na bexiga obstruída, o objetivo deste estudo foi avaliar a expressão gênica de colágeno, MMPs e seus inibidores na bexiga de pacientes com obstrução infravesical. Material e Métodos: Foi realizada uma análise prospectiva e controlada de 43 pacientes com OIV devido a HPB, que foram submetidos à ressecção transuretral da próstata (RTUP) entre 2011 e 2012. Como grupo controle foram selecionados espécimes de músculo detrusor de 10 pacientes que foram submetidos a prostatectomia radical retropúbica devido adenocarcinoma de próstata. Todos estes pacientes tinham idade menor que 60 anos, tamanho de próstata menor que 30 gramas ao ultra-som e escore internacional de sintomas prostáticos (IPSS) menor que 7. Todos os pacientes foram submetidos a estudo urodinâmico pré e pós operatório (após 6 meses). A biópsia de fragmento de músculo da bexiga foi realizada ao final da RTUP e colocada em solução estabilizadora de RNA para quantificação da expressão de colágenos I e III, metaloproteinases de matriz 1, 2 e 9, e inibidores de MMPs (TIMP1, TIMP2 e RECK) na bexiga de pacientes com HPB. Os genes descritos foram avaliados através da técnica de reação em cadeia da polimerase quantitativa em tempo real (qRT-PCR). Resultados: Todos os pacientes com HPB tinham confirmado OIV, através da análise do estudo urodinâmico (média de pressão detrusora no fluxo máximo de 78,5 cmH2O e fluxo urinário máximo de 7,7 ml / s). O gene MMP1 mostrou-se superexpresso em pacientes com HPB (mediana = 1,87). MMP9, TIMP1 e RECK estavam subexpressos na maioria dos casos, enquanto TIMP2, colágeno I e III foram superexpressos (1,5, 4,4 e 1,9 vezes, respectivamente). No que diz respeito às características clínicas e urodinâmicas encontramos que MMP2 foi mais expresso entre pacientes com um baixo IPSS global (0,005) e sem urgência (p=0,035). Colágeno III foi mais expresso em pacientes com contrações vesicais não inibidas (p = 0,049). Os outros genes não mostraram nenhuma correlação estatística com quaisquer características clínicas ou urodinâmicas. Após 6 meses de RTU, pacientes que possuíam expressão aumentada de duas ou mais MMPs, apresentaram resolução da CNI em 66,6% dos casos, contra 14,0% quando apenas uma ou nenhuma MMP estava aumentada (p=0,038) Conclusões: Encontramos um perfil de superexpressão de MMP1, TIMP2, colágenos I e III, e expressão baixa de MMP9, TIMP1 e RECK nos pacientes com OIV. Considerando o escore de sintomas prostáticos e a urgência miccional, encontramos curiosamente uma maior expressão de MMP2 em pacientes menos sintomáticos e sem urgência miccional. Encontramos uma associação entre a maior expressão de colágeno III com HD. A expressão aumentada de duas ou mais MMPs está relacionada à maiores taxas de resolução das CNIs. / Introduction: Long-term Bladder outlet obstruction (BOO) secondary to Benign prostatic Hyperplasia (BPH) can cause functional and morphological abnormalities in the bladder, such as increased collagen deposition and loss of compliance, leading to urinary storage and voiding symptoms. A decrease in bladder compliance is known to be correlated with deterioration of renal function. Increased deposition of collagen in the extracellular matrix (ECM) is the primary reason for a decreased compliance. In the bladder, as in other organs, this phenomenon is dependent on the balanced activity of proteolytic enzymes, including matrix metalloproteinases (MMPs) and their endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs). The imbalance between MMPs and TIMPs is a key regulator in ECM turnover. Since these mechanisms are unknown in the obstructed bladder, the objective of this study was to evaluate gene expression of collagen, MMPs and their inhibitors in patients with bladder outlet obstruction due to BPH. Material and Methods: We performed a prospective and controlled analysis of 43 patients with BOO due to BPH who underwent transurethral resection of the prostate (TURP) from 2011 to 2012. The control group was comprised of 10 bladder specimens from patients with < 60 years who underwent radical prostatectomy with an International Prostatic Symptom Score (IPSS) < 8 and prostate volume < 30 grams. All patients underwent urodynamic analysis pre and post operatively after 6 months. A biopsy of the bladder muscle was performed at the end of TURP for analysis of collagen, metalloproteinases and TIMPs gene expressions. For this purpose we used the quantitative real time polymerase chain reaction method (qRT-PCR). Results: All patients with BPH had confirmed BOO confirmed through urodynamic analysis (mean detrusor pressure at maximun flow 78.5 cmH2O and mean maximun flow 7.7 ml/s). MMP1 gene showed an important an overexpression in patients with BPH (median = 1.87). A similar phenomenon occurred in a lesser extent to MMP2, to which 13 of 23 subjects had under-expression (mean = 1.2). MMP9, TIMP1 and RECK were under-expressed in the majority of cases, while TIMP2, colagen I and III were over-expressed (1.5, 4.4 and 1.9x respectively) (figure). With regard to clinical and urodynamic characteristics we found that MMP2 was more over-expressed among patients with a low global IPSS (0.005) and without urgency (p=0.035). Colagen III was more over-expressed in patients with non-inhibited bladder contractions (p=0.049), RECK was more over-expressed in patients with a decreased complacence (p=0.049). The other genes showed no statistical correlation with any clinical or urodynamic characteristics. After 6 months of TURP, patients with non-inhibited bladder contractions showed resolution in 66.6% of cases, when had increased expression of two or more (> 02) MMPs in patients compared with 14.0% when only 01 MMP was increased (p = 0.038) Conclusions: BOO is related with an over-expression of MMP1, TIMP2, colagens I and III, and with an under-expression of MMP9, TIMP1 and RECK. Detrusor overactivity is related with higher collagen III expression, this fact may be due to a lower MMP1 expression. A lower global IPSS and no urgency were related to a higher expression of MMP2, sugesting that this gene may be inhibiting collagen deposition in the bladder. The increased expression of two or more MMPs isrelated to greater rates of resolution of non-inhibited bladder contractions
|
87 |
Localisation of kallikreins in the prostate and association with prostate cancer progressionBui, Loan Thuy January 2006 (has links)
At present, prostate cancer is a significant public health issue throughout the world and is the second leading cause of cancer deaths in older men. The prostate specific antigen or PSA (which is encoded by the kallikrein 3/KLK3 gene) test is the current most valuable tool for the diagnosis and management of prostate cancer. However, it is insufficiently sensitive and specific for early diagnosis, for staging of prostate cancer or for discriminating between benign prostatic hyperplasia (BPH) and prostate cancer. Recent research has revealed another potential tumour marker, glandular kallikrein 2 (KLK2 gene/hK2 protein), which may be used alone or in conjunction with PSA to overcome some of the limitations of the PSA test. Twelve new kallikrein gene family members have been recently identified and, like hK2 and PSA, many of these genes have been suggested to be involved in carcinogenesis. In this study, the cellular localisation and level of expression of several of these newer kallikreins (KLK4, KLK5, KLK7, KLK8 and KLK11) was examined in prostate tissue, to provide an understanding of the association of their expression with prostatic diseases and their potential as additional biomarkers. Like PSA and hK2, the present observation indicated that each of these proteins, hK4, hK5, hK7, hK8 and hK11, was detected within the cytoplasm of the secretory cells of the prostate glands. For the first time, all of these newly-identified proteins were shown to be expressed in prostatic intraepithelial neoplasia (PIN) lesions, in comparison to normal glands and cancer lesions. In addition to cytoplasmic secretory cell expression, the localisation of hK4 to the basal cells and nuclei in prostatic lesions was intriguing. The intensity of hK4 staining in prostate tissue was strongest in comparison to the other newly-identified kallikrein proteins (hK5, hK7, hK8 and hK11). Therefore, KLK4/hK4 expression was characterised further to define this cellular localisation and examined in non-prostatic tissue and also in a larger number of prostate tissues in an attempt to determine its potential value as a biomarker for prostate disease. Three hK4 antipeptide polyclonal antibodies, derived against N-terminal, mid-region and C-terminal hK4 amino acid sequences, were used. The hK4 N-terminal antipeptide antibody was used to demonstrate the cellular localisation of hK4 in kidney, salivary glands, liver, testis, colon carcinoma, heart, endometrium and ovarian cancer, for the first time. The presence of hK4 in these non-prostate tissues was consistent with the previous reports using RT-PCR. The dual cytoplasmic and nuclear localisation of hK4 observed in the prostate above was also seen in these tissues. Although hK4 was found widely expressed in many human tissue types, indicating that it is not prostate specific in its expression, the highest expression level of hK4 was seen in the prostate. Therefore, detailed expression patterns and levels of KLK4 mRNA and hK4 protein in the normal prostate and prostatic diseases and histopathological lesions were investigated and reported for the first time in this study. Twelve benign prostatic hyperplasia (BPH), 19 adenocarcinoma (Gleason grade 2-5) and 34 bone metastases from prostate cancer were analysed. Using in situ hybridisation, the expression of KLK4 mRNA was detected in the cytoplasm of the secretory cells of both normal and diseased prostate tissue. KLK4 mRNA was also noted in both secretory and basal cells of PIN lesions, but the basal cells of normal glands were negative. Using the hK4 N-terminal and mid-region antipeptide antibodies, hK4 was predominantly localised in the cytoplasm of the secretory cells. The intensity of hK4 staining appeared lowest in normal and BPH, and increased in PIN lesions, high Gleason grade prostate cancer and bone metastases indicating the potential of hK4 as a histopathological marker for prostatic neoplasias. Further studies are required with a larger cohort to determine its utility as a clinical biomarker. Small foci of atypical cells, which were found within normal glands, were also intensely stained. Surprisingly, hK4 protein was found in the nucleus of the secretory cells (but not the basal cells) of high grade PIN and Gleason grade 3 prostate cancer. The detection of KLK4 mRNA and hK4 protein in PIN lesions and small foci of atypical cells suggests that up-regulation of KLK4 expression occurs early in the pathology of prostate carcinogenesis. The finding of basal cell expression is not typical for the kallikreins and it is not clear what role hK4 would play in this cell type. With the use of the hK4 C-terminal antipeptide antibody, the staining was mainly localised in the nuclei of the secretory cells of the prostate glands. Although the nuclear localisation was readily noted in more than 90% of epithelial cells of the prostate gland with the C-terminal antibody, no difference in staining intensity was observed among the histopathological lesions of the prostate. The prominent nuclear localisation with the C-terminal antipeptide antibody was also shown to be distributed throughout the nucleus by using confocal microscopy. Further, by using gold-labelled particles for electron microscopy, the intracellular localisation of these hK4 antipeptide antibodies was reported here for the first time. Similar to the immunohistochemical results, the cytoplasm was the major site of localisation with the N-terminal and mid-region antipeptide antibodies. To further characterise the involvement of KLK4/hK4 in human prostate cancer progression, the transgenic adenocarcinoma mouse prostate (TRAMP) model was used in this study. In this study, mouse KLK4 (also known as enamel matrix serine protease -1, EMSP-1) was shown to be expressed in the TRAMP prostate for the first time. Previous studies had only shown the developing tooth as a site of expression for EMSP-1. The level of EMSP-1 mRNA expression was increased in PIN and prostate cancer lesions of the TRAMP model, while negative or low levels of EMSP-1 mRNA were seen in normal glands or in control mouse prostate tissue. The normal mouse prostate did not stain with any the three hK4 antipeptide antibodies. hK4 N-terminal and mid-region antipeptide antibodies showed positive staining in the cytoplasm of the epithelial cells of PIN and cancer lesions of the mouse prostate. The C-terminal antipeptide antibody showed distinctively nuclear staining and was predominantly localised in the nuclei of the glandular cells of PIN and cancer lesions of the mouse prostate. The expression patterns of both the mRNA and protein level for mouse KLK4 strongly supported the observations of KLK4/hK4 expression in the human prostate and further support the utility of the TRAMP model. Overall, the findings in this thesis indicate a clear association of KLK4/hK4 expression with prostate cancer progression. In addition, several intriguing findings were made in terms of cellular localisation (basal as well as secretory cells; nuclear and cytoplasmic) and high expression in atypical glandular cells and PIN, perhaps indicating an early involvement in prostate disease progression and, additionally, utility as basal cell and PIN histological markers. These findings provide the basis for future studies to confirm the utility of hK4 as a biomarker for prostate cancer progression and identify functional roles in the different cellular compartments.
|
88 |
Análise da expressão das metaloproteinases e seus inibidores teciduais no músculo detrusor de pacientes com obstrução infravesical por hiperplasia prostática benigna / Expression of metalloproteinases and their tissue inhibitors in the detrusor muscle of patients with bladder outlet obstruction due to benign prostatic hyperplasiaYuri Afonso Ferreira 03 October 2014 (has links)
Introdução: A obstrução infravesical (OIV) de longo prazo secundária a hiperplasia prostática benigna (HPB) pode causar alterações funcionais e morfológicas na bexiga. Um dos principais eventos consiste no aumento da deposição de colágeno e perda de complacência vesical, levando a alteração de armazenamento e esvaziamento urinário. O aumento da deposição de colágeno na matriz extracelular (MEC) da musculatura detrusora é a principal razão para a diminuição da complacência vesical. Na bexiga, assim como em outros órgãos, este fenômeno depende da atividade equilibrada de enzimas proteolíticas, incluindo as metaloproteinases (MMP) e os seus inibidores endógenos (inibidores teciduais de metaloproteinases-TIMPs). Como estes fenômenos são desconhecidos na bexiga obstruída, o objetivo deste estudo foi avaliar a expressão gênica de colágeno, MMPs e seus inibidores na bexiga de pacientes com obstrução infravesical. Material e Métodos: Foi realizada uma análise prospectiva e controlada de 43 pacientes com OIV devido a HPB, que foram submetidos à ressecção transuretral da próstata (RTUP) entre 2011 e 2012. Como grupo controle foram selecionados espécimes de músculo detrusor de 10 pacientes que foram submetidos a prostatectomia radical retropúbica devido adenocarcinoma de próstata. Todos estes pacientes tinham idade menor que 60 anos, tamanho de próstata menor que 30 gramas ao ultra-som e escore internacional de sintomas prostáticos (IPSS) menor que 7. Todos os pacientes foram submetidos a estudo urodinâmico pré e pós operatório (após 6 meses). A biópsia de fragmento de músculo da bexiga foi realizada ao final da RTUP e colocada em solução estabilizadora de RNA para quantificação da expressão de colágenos I e III, metaloproteinases de matriz 1, 2 e 9, e inibidores de MMPs (TIMP1, TIMP2 e RECK) na bexiga de pacientes com HPB. Os genes descritos foram avaliados através da técnica de reação em cadeia da polimerase quantitativa em tempo real (qRT-PCR). Resultados: Todos os pacientes com HPB tinham confirmado OIV, através da análise do estudo urodinâmico (média de pressão detrusora no fluxo máximo de 78,5 cmH2O e fluxo urinário máximo de 7,7 ml / s). O gene MMP1 mostrou-se superexpresso em pacientes com HPB (mediana = 1,87). MMP9, TIMP1 e RECK estavam subexpressos na maioria dos casos, enquanto TIMP2, colágeno I e III foram superexpressos (1,5, 4,4 e 1,9 vezes, respectivamente). No que diz respeito às características clínicas e urodinâmicas encontramos que MMP2 foi mais expresso entre pacientes com um baixo IPSS global (0,005) e sem urgência (p=0,035). Colágeno III foi mais expresso em pacientes com contrações vesicais não inibidas (p = 0,049). Os outros genes não mostraram nenhuma correlação estatística com quaisquer características clínicas ou urodinâmicas. Após 6 meses de RTU, pacientes que possuíam expressão aumentada de duas ou mais MMPs, apresentaram resolução da CNI em 66,6% dos casos, contra 14,0% quando apenas uma ou nenhuma MMP estava aumentada (p=0,038) Conclusões: Encontramos um perfil de superexpressão de MMP1, TIMP2, colágenos I e III, e expressão baixa de MMP9, TIMP1 e RECK nos pacientes com OIV. Considerando o escore de sintomas prostáticos e a urgência miccional, encontramos curiosamente uma maior expressão de MMP2 em pacientes menos sintomáticos e sem urgência miccional. Encontramos uma associação entre a maior expressão de colágeno III com HD. A expressão aumentada de duas ou mais MMPs está relacionada à maiores taxas de resolução das CNIs. / Introduction: Long-term Bladder outlet obstruction (BOO) secondary to Benign prostatic Hyperplasia (BPH) can cause functional and morphological abnormalities in the bladder, such as increased collagen deposition and loss of compliance, leading to urinary storage and voiding symptoms. A decrease in bladder compliance is known to be correlated with deterioration of renal function. Increased deposition of collagen in the extracellular matrix (ECM) is the primary reason for a decreased compliance. In the bladder, as in other organs, this phenomenon is dependent on the balanced activity of proteolytic enzymes, including matrix metalloproteinases (MMPs) and their endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs). The imbalance between MMPs and TIMPs is a key regulator in ECM turnover. Since these mechanisms are unknown in the obstructed bladder, the objective of this study was to evaluate gene expression of collagen, MMPs and their inhibitors in patients with bladder outlet obstruction due to BPH. Material and Methods: We performed a prospective and controlled analysis of 43 patients with BOO due to BPH who underwent transurethral resection of the prostate (TURP) from 2011 to 2012. The control group was comprised of 10 bladder specimens from patients with < 60 years who underwent radical prostatectomy with an International Prostatic Symptom Score (IPSS) < 8 and prostate volume < 30 grams. All patients underwent urodynamic analysis pre and post operatively after 6 months. A biopsy of the bladder muscle was performed at the end of TURP for analysis of collagen, metalloproteinases and TIMPs gene expressions. For this purpose we used the quantitative real time polymerase chain reaction method (qRT-PCR). Results: All patients with BPH had confirmed BOO confirmed through urodynamic analysis (mean detrusor pressure at maximun flow 78.5 cmH2O and mean maximun flow 7.7 ml/s). MMP1 gene showed an important an overexpression in patients with BPH (median = 1.87). A similar phenomenon occurred in a lesser extent to MMP2, to which 13 of 23 subjects had under-expression (mean = 1.2). MMP9, TIMP1 and RECK were under-expressed in the majority of cases, while TIMP2, colagen I and III were over-expressed (1.5, 4.4 and 1.9x respectively) (figure). With regard to clinical and urodynamic characteristics we found that MMP2 was more over-expressed among patients with a low global IPSS (0.005) and without urgency (p=0.035). Colagen III was more over-expressed in patients with non-inhibited bladder contractions (p=0.049), RECK was more over-expressed in patients with a decreased complacence (p=0.049). The other genes showed no statistical correlation with any clinical or urodynamic characteristics. After 6 months of TURP, patients with non-inhibited bladder contractions showed resolution in 66.6% of cases, when had increased expression of two or more (> 02) MMPs in patients compared with 14.0% when only 01 MMP was increased (p = 0.038) Conclusions: BOO is related with an over-expression of MMP1, TIMP2, colagens I and III, and with an under-expression of MMP9, TIMP1 and RECK. Detrusor overactivity is related with higher collagen III expression, this fact may be due to a lower MMP1 expression. A lower global IPSS and no urgency were related to a higher expression of MMP2, sugesting that this gene may be inhibiting collagen deposition in the bladder. The increased expression of two or more MMPs isrelated to greater rates of resolution of non-inhibited bladder contractions
|
Page generated in 0.0994 seconds